AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Annexon Inc (NASDAQ:ANNX)
2.435 USD
+0.045 1.883%Sponsored Reports
Loading...
| Previous Close (in USD) | 2.39 |
|---|---|
| Change | +0.045 1.883% |
| 52 W H/L (in USD) | 8.400/2.340 |
| EBITDA (in USD) | -124.791M |
| PE Ratio | -- |
| Volume | 513402 |
| Diluted Eps TTM | -1.03 |
| Total Assets (in USD) | 297.674M |
|---|---|
| Total Liabilities (in USD) | 47.118M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 225.11M |
| Market Cap (in USD) | 528.706 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
1400 Sierra Point Parkway, Brisbane, CA, United States, 94005
650 822 5500
Employees: 71
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Douglas Love J.D., Esq. | CEO, Pres & Director | 1968 |
| 2. | Dr. Larry C. Mattheakis Ph.D. | Exec. VP & Chief Scientific Officer | 1957 |
| 3. | Dr. Ted Yednock Ph.D. | Exec. VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | 1958 |
| 4. | Dr. Arnon Rosenthal Ph.D. | Founder | 1956 |
| 5. | Ms. Jennifer Lew | Exec. VP & CFO | 1973 |
| 6. | Miriam Mason | Sr. VP of Corp. Communications | NA |
| 7. | Mr. Michael Overdorf M.B.A. | Exec. VP & Chief Bus. Officer | 1970 |
| 8. | Henk-Andre Kroon M.D. | Sr. VP of Translational Medicine | NA |
| 9. | Mirella Villa Del Toro | Sec. | NA |
| 10. | Mr. Douglas Love Esq., J.D. | CEO, President & Director | 1968 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.140 0.208% | 67.62 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.510 0.756% | 68.9 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-3.525 0.791% | 445.82 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-0.870 0.167% | 520 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -141.947M | -130.323M | -63.412M | -37.179M | -18.303M |
| Minority Interest | - | - | - | - | - |
| Net Income | -138.295M | -127.792M | -62.745M | -37.183M | -18.304M |
| Selling General Administrative | 33.098M | 30.647M | 14.198M | 7.994M | 3.619M |
| Gross Profit | - | - | - | - | - |
| Reconciled Depreciation | 2.106M | 2.141M | 0.667M | 0.493M | 0.488M |
| Ebit | -147.705M | -132.854M | -64.136M | -32.518M | -19.147M |
| Ebitda | -145.599M | -130.713M | -63.469M | -32.025M | -18.659M |
| Depreciation And Amortization | 2.106M | 2.141M | 0.667M | 0.493M | 0.488M |
| Operating Income | -145.599M | -130.713M | -63.469M | -32.518M | -19.147M |
| Other Operating Expenses | 145.599M | 130.713M | 63.469M | 32.518M | 19.147M |
| Interest Expense | 3.652M | 2.141M | 0M | 4.661M | 0M |
| Tax Provision | - | 0M | 0M | 0.004M | 0.001M |
| Interest Income | 3.652M | 0.39M | - | 0.014M | 0.04M |
| Net Interest Income | 3.652M | 0.39M | - | - | - |
| Income Tax Expense | -3.652M | -2.531M | -0.667M | 0.004M | 0.001M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 145.599M | 130.713M | 63.469M | 32.518M | 19.147M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 3.652M | 0.39M | 0.057M | -4.661M | 0.844M |
| Net Income From Continuing Ops | -145.599M | -130.713M | -63.412M | -37.183M | -18.304M |
| Net Income Applicable To Common Shares | -141.947M | -130.323M | -70.336M | -38.278M | -18.48M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 297.674M | 285.096M | 287.04M | 355.946M | 49.898M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 4.144M | 5.441M | 4.978M | 2.805M | 1.396M |
| Total Liab | 47.118M | 53.902M | 55.131M | 11.668M | 6.368M |
| Total Stockholder Equity | 250.556M | 231.194M | 231.909M | 344.278M | 43.53M |
| Other Current Liab | 10.276M | 13.628M | 0.139M | 6.888M | 2.56M |
| Common Stock | 0.078M | 0.048M | 0.039M | 0.038M | 0.004M |
| Capital Stock | 0.078M | 0.048M | 0.039M | 0.038M | 143.988M |
| Retained Earnings | -572.499M | -438.262M | -296.315M | -165.992M | -102.58M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 1.032M | 1.166M | - | 2.354M |
| Cash | 225.11M | 140.02M | 74.843M | 268.565M | 43.931M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 17.928M | 22.36M | 21.744M | 10.622M | 4.931M |
| Current Deferred Revenue | - | - | 9.25M | - | - |
| Net Debt | -193.755M | -107.162M | -40.254M | -268.565M | -43.931M |
| Short Term Debt | 2.165M | 1.316M | 1.202M | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 31.355M | 32.858M | 34.589M | - | - |
| Other Stockholder Equity | 823.029M | 669.78M | 528.365M | 154.363M | 2.202M |
| Property Plant Equipment | - | 16.838M | 38.181M | 1.935M | 2.138M |
| Total Current Assets | 263.86M | 248.098M | 247.693M | 354.011M | 45.406M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 34.606M | 102.637M | 167.872M | 82.641M | - |
| Net Receivables | - | - | - | 0.003M | 0.079M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | -0.003M | - |
| Accounts Payable | 5.487M | 7.416M | 11.153M | 3.734M | 2.371M |
| Accumulated Other Comprehensive Income | -0.052M | -0.372M | -0.18M | -0.077M | -0.08M |
| Non Currrent Assets Other | 1.032M | 1.032M | 1.166M | - | 2.354M |
| Non Current Assets Total | 33.814M | 36.998M | 39.347M | 1.935M | 4.492M |
| Capital Lease Obligations | 31.355M | 32.858M | 34.589M | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 64.969M | -86.582M | -83.164M | -0.267M | -0.017M |
| Total Cashflows From Investing Activities | 58.443M | -88.236M | -83.164M | -0.267M | -0.017M |
| Total Cash From Financing Activities | 122.908M | 1.795M | 360.876M | 28.395M | 58.456M |
| Net Income | -141.947M | -130.323M | -63.412M | -37.183M | -18.304M |
| Change In Cash | 65.043M | -192.556M | 224.634M | -0.244M | 41.209M |
| Begin Period Cash Flow | 76.009M | 268.565M | 43.931M | 44.175M | 2.966M |
| End Period Cash Flow | 141.052M | 76.009M | 268.565M | 43.931M | 44.175M |
| Total Cash From Operating Activities | -116.309M | -106.11M | -53.087M | -28.358M | -17.19M |
| Depreciation | 2.106M | 2.141M | 0.667M | 0.493M | 0.488M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | -102.522M | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 121.396M | 1.795M | -5.193M | 30M | 58.456M |
| Other Cashflows From Financing Activities | -7.568M | 1.795M | 202.07M | 28.395M | 58.456M |
| Capital Expenditures | 6.526M | 1.654M | 0.464M | 0.267M | 0.017M |
| Change In Working Capital | 3.738M | 3.284M | 4.717M | 0.625M | 0.478M |
| Other Non Cash Items | 1.278M | 1.273M | 0.053M | 5.67M | -0.26M |
| Free Cash Flow | -122.835M | -107.764M | -53.551M | -28.625M | -17.207M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BB Biotech AG Ord | 8 months ago | 5157290 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 3009244 |
| 3. | iShares Russell 2000 ETF | 6 months ago | 2675893 |
| 4. | Fidelity Growth Compy Commingled Pl S | 7 months ago | 2404169 |
| 5. | Candriam Eqs L Biotech C USD Cap | 7 months ago | 2013148 |
| 6. | SPDR® S&P Biotech ETF | 6 months ago | 1903004 |
| 7. | Fidelity Growth Company Fund | 7 months ago | 1781431 |
| 8. | Fidelity Small Cap Growth | 8 months ago | 1331756 |
| 9. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 1299301 |
| 10. | Nuveen Quant Small Cap Equity R6 | 8 months ago | 1103900 |
| 11. | CREF Stock R1 | 9 months ago | 1078540 |
| 12. | Fidelity Small Cap Index | 8 months ago | 973252 |
| 13. | iShares Russell 2000 Value ETF | 6 months ago | 936132 |
| 14. | Rhenman Healthcare Equity L/S RC2 SEK | 9 months ago | 900000 |
| 15. | Fidelity Advisor Biotechnology I | 7 months ago | 791648 |
| 16. | MFS New Discovery I | 7 months ago | 668226 |
| 17. | State St Russell Sm/Mid Cp® Indx NL Cl C | 7 months ago | 625088 |
| 18. | JPMorgan US Small Company L | 7 months ago | 623847 |
| 19. | Fidelity Small Cap Growth K6 | 8 months ago | 541183 |
| 20. | Fidelity Growth Company K6 | 7 months ago | 538692 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | FMR Inc | 8 months ago | 8561949 |
| 2. | Bain Capital Life Sciences Investors, LLC | 8 months ago | 8449748 |
| 3. | SATTER MANAGEMENT CO., L.P. | 8 months ago | 7406024 |
| 4. | Bvf Inc | 8 months ago | 7000000 |
| 5. | BlackRock Inc | 11 months ago | 6587287 |
| 6. | Redmile Group, LLC | 8 months ago | 6427462 |
| 7. | Point72 Asset Management, L.P. | 8 months ago | 5326998 |
| 8. | Bellevue Group AG | 8 months ago | 5157290 |
| 9. | Vanguard Group Inc | 8 months ago | 4970293 |
| 10. | State Street Corp | 8 months ago | 3841879 |
| 11. | Woodline Partners LP | 8 months ago | 3430160 |
| 12. | Adage Capital Partners Gp LLC | 8 months ago | 2840145 |
| 13. | Logos Global Management LP | 8 months ago | 2600000 |
| 14. | Nuveen Asset Management, LLC | 8 months ago | 2555570 |
| 15. | Candriam Luxembourg S.C.A. | 8 months ago | 2192799 |
| 16. | Geode Capital Management, LLC | 8 months ago | 2143635 |
| 17. | GMT Capital Corp | 8 months ago | 1908366 |
| 18. | Goldman Sachs Group Inc | 8 months ago | 1904378 |
| 19. | JPMorgan Chase & Co | 8 months ago | 1706182 |
| 20. | Kennedy Capital Management Inc | 8 months ago | 1450895 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...